Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frauke Stascheit

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Acta Neuropathologica|September 19, 2025
Complement profiling of sural nerves in chronic-inflammatory demyelinating polyneuropathyFrauke Stascheit, Andreas Roos, Christina B Schroeter, et al.
Frontiers in Neurology|March 12, 2024
Identifying patients at risk for myasthenic crisis with hemogram and inflammation-related laboratory parameters - a pilot studyAnne Mehnert, Sivan Bershan, Jil Kollmus-Heege, et al.
JCI Insight|May 25, 2023
Eculizumab treatment alters the proteometabolome beyond the inhibition of complementChristopher Nelke, Christina B Schroeter, Frauke Stascheit, et al.
Annals of Clinical and Translational Neurology|November 20, 2025
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and EculizumabLea Gerischer, Frauke Stascheit, Maximilian Mönch, et al.
Neurology|July 6, 2026
Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis RegistryHannah Preßler, Frauke Stascheit, Annette Aigner, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 21, 2025
Single-Cell Transcriptomics Identifies a Prominent Role for the MIF-CD74 Axis in Myasthenia Gravis ThymusPaula Terroba-Navajas, I-Na Lu, Isaak Quast, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 27, 2024
Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World StudyFrauke Stascheit, Carla Daiane Ferreira de Sousa, Annette Aigner, et al.
Journal of Neuroinflammation|April 13, 2022
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patientsChristopher Nelke, Frauke Stascheit, Carmen Eckert, et al.
Ebiomedicine|July 3, 2024
Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clusteringChristopher Nelke, Christina B Schroeter, Sumanta Barman, et al.
Orphanet Journal of Rare Diseases|March 12, 2025
Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable dataAbderhmane Slioui, Giulia Tammam, Fiammetta Vanoli, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Acta Neuropathologica|September 19, 2025
Complement profiling of sural nerves in chronic-inflammatory demyelinating polyneuropathyFrauke Stascheit, Andreas Roos, Christina B Schroeter, et al.
Frontiers in Neurology|March 12, 2024
Identifying patients at risk for myasthenic crisis with hemogram and inflammation-related laboratory parameters - a pilot studyAnne Mehnert, Sivan Bershan, Jil Kollmus-Heege, et al.
JCI Insight|May 25, 2023
Eculizumab treatment alters the proteometabolome beyond the inhibition of complementChristopher Nelke, Christina B Schroeter, Frauke Stascheit, et al.
Annals of Clinical and Translational Neurology|November 20, 2025
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and EculizumabLea Gerischer, Frauke Stascheit, Maximilian Mönch, et al.
Neurology|July 6, 2026
Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis RegistryHannah Preßler, Frauke Stascheit, Annette Aigner, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|March 21, 2025
Single-Cell Transcriptomics Identifies a Prominent Role for the MIF-CD74 Axis in Myasthenia Gravis ThymusPaula Terroba-Navajas, I-Na Lu, Isaak Quast, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|November 27, 2024
Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World StudyFrauke Stascheit, Carla Daiane Ferreira de Sousa, Annette Aigner, et al.
Journal of Neuroinflammation|April 13, 2022
Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patientsChristopher Nelke, Frauke Stascheit, Carmen Eckert, et al.
Ebiomedicine|July 3, 2024
Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clusteringChristopher Nelke, Christina B Schroeter, Sumanta Barman, et al.
Orphanet Journal of Rare Diseases|March 12, 2025
Toward European harmonization of national myasthenia gravis registries: modified Delphi procedure-based expert consensus on collectable dataAbderhmane Slioui, Giulia Tammam, Fiammetta Vanoli, et al.
Pageof 6